[{"orgOrder":0,"company":"Athenex","sponsor":"Alter Pharma group","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2023","type":"Inapplicable","leadProduct":"Magnesium Sulfate","moa":"||Undisclosed","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Athenex","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Athenex \/ Alter Pharma group","highestDevelopmentStatusID":"15","companyTruncated":"Athenex \/ Alter Pharma group"},{"orgOrder":0,"company":"General Committee of Teaching Hospitals and Institutes, Egypt","sponsor":"Ain Shams University | Health Insurance Organization, Egypt","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Inapplicable","leadProduct":"Magnesium Sulfate","moa":"||N-methyl-D-aspartate receptor (NMDAR)","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"General Committee of Teaching Hospitals and Institutes, Egypt","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"General Committee of Teaching Hospitals and Institutes, Egypt \/ Ain Shams University | Health Insurance Organization, Egypt","highestDevelopmentStatusID":"9","companyTruncated":"General Committee of Teaching Hospitals and Institutes, Egypt \/ Ain Shams University | Health Insurance Organization, Egypt"},{"orgOrder":0,"company":"NYU Langone Health","sponsor":"National Heart, Lung, and Blood Institute","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2024","type":"Inapplicable","leadProduct":"Magnesium Sulfate","moa":"||N-methyl-D-aspartate receptor (NMDAR)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"NYU Langone Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"NYU Langone Health \/ National Heart, Lung, and Blood Institute","highestDevelopmentStatusID":"6","companyTruncated":"NYU Langone Health \/ National Heart, Lung, and Blood Institute"},{"orgOrder":0,"company":"Avenacy","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2024","type":"Inapplicable","leadProduct":"Magnesium Sulfate","moa":"||Undisclosed","graph1":"Neurology","graph2":"Approved FDF","graph3":"Avenacy","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Avenacy \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Avenacy \/ Inapplicable"},{"orgOrder":0,"company":"NYU Langone Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2024","type":"Inapplicable","leadProduct":"Magnesium Sulfate","moa":"||N-methyl-D-aspartate receptor (NMDAR)","graph1":"Undisclosed","graph2":"Phase IV","graph3":"NYU Langone Health","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"NYU Langone Health \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"NYU Langone Health \/ Inapplicable"},{"orgOrder":0,"company":"Sunnybrook Health Sciences Centre","sponsor":"Sunnybrook Research Institute","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2022","type":"Inapplicable","leadProduct":"Magnesium Sulfate","moa":"||N-methyl-D-aspartate receptor (NMDAR)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Sunnybrook Health Sciences Centre","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sunnybrook Health Sciences Centre \/ Sunnybrook Research Institute","highestDevelopmentStatusID":"10","companyTruncated":"Sunnybrook Health Sciences Centre \/ Sunnybrook Research Institute"}]

Find Clinical Drug Pipeline Developments & Deals for MAGNESIUM SULFATE ANHYDROUS

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Vitamins/Minerals/Inorganic Salts

                          Upfront Cash : Inapplicable

                          June 27, 2024

                          Lead Product(s) : Magnesium Sulfate,Inapplicable

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase IV

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Vitamins/Minerals/Inorganic Salts

                          Upfront Cash : Inapplicable

                          June 12, 2024

                          Lead Product(s) : Magnesium Sulfate,Inapplicable

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Phase I

                          Sponsor : National Heart, Lung, and Blood Institute

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Magnesium Sulfate in Water for Injection is a NMDA inhibitor, indicated for the prevention and control of seizures in preeclampsia and eclampsia.

                          Product Name : Magnesium Sulfate-Generic

                          Product Type : Vitamins/Minerals/Inorganic Salts

                          Upfront Cash : Inapplicable

                          May 14, 2024

                          Lead Product(s) : Magnesium Sulfate,Inapplicable

                          Therapeutic Area : Neurology

                          Highest Development Status : Approved FDF

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Magnesium sulfate injection is indicated for the prevention and control of seizures in preeclampsia and eclampsia. It reduces striated muscle contractions and blocks peripheral neuromuscular transmission by reducing acetylcholine release at the myoneural...

                          Product Name : Magnesium Sulfate-Generic

                          Product Type : Vitamins/Minerals/Inorganic Salts

                          Upfront Cash : Inapplicable

                          March 20, 2023

                          Lead Product(s) : Magnesium Sulfate,Inapplicable

                          Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                          Highest Development Status : Approved FDF

                          Sponsor : Alter Pharma group

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          Sunnybrook Health Sciences Centre

                          Country arrow
                          EPSC
                          Not Confirmed

                          Sunnybrook Health Sciences Centre

                          Country arrow
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Vitamins/Minerals/Inorganic Salts

                          Upfront Cash : Inapplicable

                          March 18, 2022

                          Lead Product(s) : Magnesium Sulfate,Digoxin

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Phase III

                          Sponsor : Sunnybrook Research Institute

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          General Committee of Teaching Hospitals and Institutes, Egypt

                          Country arrow
                          EPSC
                          Not Confirmed

                          General Committee of Teaching Hospitals and Institutes, Egypt

                          Country arrow
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Vitamins/Minerals/Inorganic Salts

                          Upfront Cash : Inapplicable

                          November 03, 2020

                          Lead Product(s) : Magnesium Sulfate,Inapplicable

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase II/ Phase III

                          Sponsor : Ain Shams University | Health Insurance Organization, Egypt

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          Linda Fu

                          Country arrow
                          EPSC
                          Not Confirmed

                          Linda Fu

                          Country arrow
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Theraworx

                          Product Type : Vitamins/Minerals/Inorganic Salts

                          Upfront Cash : Inapplicable

                          September 24, 2019

                          Lead Product(s) : Magnesium Sulfate,Inapplicable

                          Therapeutic Area : Dermatology

                          Highest Development Status : Phase IV

                          Sponsor : Avadim Technologies

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          James Cook University Hospital

                          Country arrow
                          EPSC
                          Not Confirmed

                          James Cook University Hospital

                          Country arrow
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          March 01, 2019

                          Lead Product(s) : Gabapentin,Lansoprazole,Paracetamol,Dexamethasone,Ondansetron,Bupivacaine,Magnesium Sulfate

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Undisclosed

                          Sponsor : Medela

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          Metabolic Therapy Inc.

                          Country arrow
                          EPSC
                          Not Confirmed

                          Metabolic Therapy Inc.

                          Country arrow
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Vitamins/Minerals/Inorganic Salts

                          Upfront Cash : Inapplicable

                          January 31, 2017

                          Lead Product(s) : Magnesium Sulfate,Inapplicable

                          Therapeutic Area : Neurology

                          Highest Development Status : Undisclosed

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          January 02, 2017

                          Lead Product(s) : Sodium Sulfate,Potassium Sulfate,Magnesium Sulfate

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank